Understanding a little about the prostate gland and its biology is not only interesting, but it allows us to ask some important questions that can positively inform our treatment decisions and eventually the outcomes. On the other hand, it also can add to the confusion we all face in making the best clinical decisions. Like [...]
Understanding a little about the prostate gland and its biology is not only interesting, but it allows us to ask some important questions that can be very specific to our prostate cancer treatment decisions and our eventual outcomes from these decisions. It also can simply add to the confusion we all face in making the [...]
Teva Pharmaceutical Industries has received approval and launched, in the United States, a generic version of the Avodart (dutasteride) capsules at the 0.5 mg dose. Avodart, 5-alpha reductase inhibitor, is FDA approved for the treatment of men with benign prostate hyperplasia (an enlarged prostate gland), however, although not approved; men often use it as a [...]
Men with metastatic castrate resistant prostate cancer (mCRPC) have become fortunate over the last few years as there we now have a number of new drugs available which can extend our life and can also have some palliative effects. However, as we have more treatments being approved, we find that we are faced with a [...]
Intermittent hormone therapy (IHT) as opposed to continuous hormone therapy (CHT) provides a better quality of life (QoL) for men with locally advanced prostate cancer. However, there is a debate created by a few major research protocols that have been inconclusive as to the difference in achieving the ultimate goal, survival despite prostate cancer. Researchers [...]
Traditional hormone therapy usually consists of two types of drugs; GnRH agonists (like Lupron and Zoladex) and antiandrogens (Casodex). Although they both are drugs that manipulate the hormone system their modes of action are different. GnRH agonists block the production of the male hormone testosterone while the antiandrogen drug blocks the ability of the prostate [...]
During last year’s American Society of Clinical Oncologists (ASCO) Annual Meeting, data was released from the STAMPEDE trial which should change clinical practice around the world. The trial results showed that newly diagnosed men with very aggressive prostate cancer that was still hormone therapy naive (no ADT) would have a very significant survival advantage by [...]
According to a recent study published in the Journal of Urology, men with localized prostate cancer on hormone therapy (ADT) have a significant increase in their risk for developing diabetes. In this retrospective study of 12,191 men with localized prostate cancer who did not have diabetes were followed once they went on ADT. It was [...]
Men who develop bone metastases have often been viewed as having developed a significant negative change that prognosticates a negative impact on both their quality of life and on their survival. Contradicting this commonly held belief has been some research which has identified a subgroup of men with advanced prostate cancer with bone metastases who [...]
Clinicians believe that there is an association between the risk of cardiovascular disease (CVD) and the duration and type of androgen-deprivation therapy (ADT) in men with prostate cancer. Researchers took data from 2006 to 2012 on filled drug prescriptions from the Swedish national health care registers. A cohort of 41,362 men with prostate cancer who were on ADT [...]
